Skip to main content
AmigoFish

After presenting data at ESMO this past weekend, Tango Therapeutics believes that adding PRMT5 to RAS inhibitors represents the 'next chapter' in today's pancreatic cancer revolution (and beyond)

From BiotechTV - News · · 21 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

President and CEO Malte Peters summarizes the ESMO data for vopemetistat, which was in second and third line pancreatic cancer in combination with daraxonrasib, and discusses plans for a phase 3 in first line (plus the regulatory path for later lines as well). Additionally, he discusses using PRMT5 inhibition in lung cancer and GBM.

Back to BiotechTV - News · Report a problem